Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties

  • Herrera-Arozamena, Clara
  • Estrada-Valencia, Martín
  • García-Díez, Guillermo
  • Pérez, Concepción
  • León, Rafael
  • Infantes, Lourdes
  • Morales-García, José A.
  • Pérez-Castillo, Ana
  • Sastre, Eric del
  • López, Manuela G.
  • Rodríguez-Franco, María Isabel
5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (3), whose structure was unambiguously elucidated by X-ray analysis, was identified as a multi-target compound with potential application in neurodegenerative diseases. It is a low nanomolar inhibitor of QR2 (IC50 = 7.7 nM), with greater potency than melatonin and comparable efficacy to the most potent QR2 inhibitors described to date. Molecular docking studies revealed the potential binding mode of 3 to QR2, which explains its superior potency compared to melatonin. Furthermore, compound 3 inhibits hMAO-A, hMAO-B and hLOX-5 in the low micromolar range and is an excellent ROS scavenger. In phenotypic assays, compound 3 showed neuroprotective activity in a cellular model of oxidative stress damage, it was non-toxic, and was able to activate neurogenesis from neural stem-cell niches of adult mice. These excellent biological properties, together with its both good in silico and in vitro drug-like profile, highlight compound 3 as a promising drug candidate for neurodegenerative diseases., Theauthors gratefully acknowledge the following financial supports: Spanish Ministry of Science, Innovation and Universities; Spanish Research Agency; and European Regional Development Funds (grants PID2021-122650OB-I00 to M.I.R.-F.; PDC2022-133809-I00 to M.G.L., R.L., and M.I.R.-F.; PID2021-123481OB-I00 to R.L.; PID2021125986OB-I00 to M.G.L.; PID2020-117400 GB-I00 to L.I.); General Council for Research and Innovation of the Community of Madrid (grant P2022/BMD-7230 to M.G.L., R.L., and M.I.R.-F.); Spanish National Research Council (CSIC, grant PIE-202480E175 to M.I.R.-F.) Compound 3 X-ray experiments were performed at BL13-XALOC beamline at ALBA Synchrotron with the collaboration of ALBA staff. We thank the Spanish Ministry of Science, Innovation and Universities for the fellowships FPU22/03672 to G.G.-D. and FPU18/00630 to E.dS. The authors acknowledge the support of the European COST Action CA20121 (BenBedPhar) and the Fundación Teófilo Hernando, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model

  • Silva-Llanes, Ignacio
  • Rodríguez-López, S.
  • González-Naranjo, Pedro
  • Sastre, E. del
  • López, Manuela G.
  • Páez, Juan A.
  • Campillo, Nuria
  • Lastres-Becker, Isabel
Frontotemporal dementia (FTD) comprises a group of disorders characterized by a progressive decline in behavior or language linked to the degeneration of the frontal and anterior temporal lobes followed by hippocampal atrophy. There are no effective treatments for FTD and for this reason, novel pharmacological targets, such as the endocannabinoid system (ECS), are being explored. Previous results from our laboratory showed a TAU-dependent increase in CB receptor expression in hippocampal neurons of a FTD mouse model, alongside the neuroprotective impact of CB ablation. In this study, we evaluated the therapeutic potential of a new CB antagonist (PGN36) in our TAU-dependent FTD mouse model. Six-month-old mice received stereotaxic injections of an adeno-associated virus expressing human TAU protein (AAV-TAU) into the right hippocampus and were treated daily with PGN36 (5 mg/kg, i.p.) or vehicle for three weeks. By integrating behavioral tests, RNA-seq, qPCR expression analysis, and immunofluorescence in the AAV expressing TAU mouse model, we found that PGN36 treatment reverses key features of the neurodegenerative process triggered by TAU overexpression. PGN36 treatment effectively countered TAU-induced cognitive decline by reducing TAU protein expression levels and restoring markers of synaptic plasticity. Notably, we observed neuroprotection in the dentate gyrus granular layer, which we attribute to the modulation of pyroptosis. This programmed cell death pathway, is triggered by TAU overexpression. PGN36 appears to modulate the pyroptotic cascade, thereby preventing the pyroptosis-induced neuronal loss. These findings collectively underscore the neuroprotective potential of this novel CB antagonist treatment against TAU-associated FTD., This work was supported by Fundación Tatiana Pérez de Guzmán el Bueno, MINECO (grants PID2019-105600RB-I00 and PID2022- 137065OB-I00 to I.L-B and PDC2022-133809-I00 to MGL), ISCiii CIBERNED (CB06/05/0089 to I. L-B.) and Community of Madrid ref CAM-P2022/BMD-7230 to MGL. FPU18/00630 contract to ES.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Health position paper and redox perspectives – Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases

  • Cuadrado, Antonio
  • Cazalla, Eduardo
  • Bach, A.
  • Bathish, B.
  • Naidu, S. D.
  • DeNicola, G. M.
  • Dinkova-Kostova, A. T.
  • Fernández-Ginés, Raquel
  • Grochot-Przeczek, A.
  • Hayes, J. D.
  • Kensler, T. W.
  • León, Rafael
  • Liby, K. T.
  • López, M. G.
  • Manda, Gina
  • Shivakumar, A. K.
  • Hakomäki, H.
  • Moerland, J. A.
  • Rojo, Ana I.
  • Sykiotis, G. P.
  • Taguchi, K.
  • Valverde, Ángela M.
  • Yamamoto, M.
  • Levonen, A. L.
This review is dedicated to the memory of Dr. Karen T. Liby, who passed away during the final editing of the manuscript. During her academic career, Karen made numerous extensive contributions to the pharmacology of Nrf2 activators, particularly to the preclinical development of the cyanoenone triterpenoids as multifunctional agents for prevention and treatment of chronic disease. Karen’s untimely passing is a huge loss for the Nrf2 community worldwide. Her kind personality and scientific rigour will be greatly missed., Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-activated transcription factor regulating cellular defense against oxidative stress, thereby playing a pivotal role in maintaining cellular homeostasis. Its dysregulation is implicated in the progression of a wide array of human diseases, making NRF2 a compelling target for therapeutic interventions. However, challenges persist in drug discovery and safe targeting of NRF2, as unresolved questions remain especially regarding its context-specific role in diseases and off-target effects. This comprehensive review discusses the dualistic role of NRF2 in disease pathophysiology, covering its protective and/or destructive roles in autoimmune, respiratory, cardiovascular, and metabolic diseases, as well as diseases of the digestive system and cancer. Additionally, we also review the development of drugs that either activate or inhibit NRF2, discuss main barriers in translating NRF2-based therapies from bench to bedside, and consider the ways to monitor NRF2 activation in vivo., U.S. National Institutes of Health, R35 CA197222 (T.W.K.). PID- 2021-122766OB-1363 100 funded by MICIU/AEI/10.13039/ 501100011033 and by ERDF/EU (A.M.V.). National Science Centre grant OPUS (2021/43/B/NZ4/02130) (A.G-P). Swiss National Science Foundation grants 310 030_212 558 and IZCOZ0_205 415 (G.P.S.). Lundbeck Foundation (grant R366-2021-270 (A.B.). Medical Research Council UK [MR/T014644/1 (J.D.H., B.B., A.T.D-K) and MR/ W023806/1 (A T.D-K)], Biotechnology and Biological Sciences Research Council UK (BB/T508111/1 and BB/X00029X/1) (A.T.D-K), Tenovus Scotland (T22-08) (S.DN, A.T.D-K), and Reata Pharmaceuticals/Biogen (S.DN, A.T.D-K). Spanish Ministry of Science, Innovation and Universities (PID-2021-122766OB-100, PDC2021-121 421-I00, PDC2022-133 765-I00), CIBERNED/ISCIII (CB06/05/0010), and The Autonomous Community of Madrid (P2022/BMD-7230) (A.C., A.I.R.). FPU contract of MIU (Ministry of Universities FPU2021, FPU21/02505) (E.C.). Spanish Ministry of Science (grant PID2021-123481OB-I00), Comunidad de Madrid (grant P2022/BMD-7230-CAM-22), and Fundación Teófilo Hernando” (R.L.). Romania Ministry of Research, Innovation and Digitization through the Nucleu grant PN23.16.02.01 (G.M.). Spanish Ministry of science innovation and universities Refs PDC2022-133 809-I00 and PID2021-125986OB-I00 and General Council for Research and Innovation of the Community of Madrid Ref. P2022/BMD-7230 to (M.G.L.). NIH National Cancer Institute: NIH F31 CA275239 (J.A.M). Cancer Foundation Finland, Sigrid Juselius Foundation (A.L.L.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Long-term NRF2-driven microglial repopulation mitigates microgliosis, neuronal loss and cognitive deficits in tauopathy

  • Viqueira, Lucía
  • Navarro, Elisa
  • Negredo, Pilar
  • Bernal, Juan Antonio
  • Rodríguez-Franco, María Isabel
  • Tortosa, Elena
  • López, Manuela G
Tauopathies, including Alzheimer's disease, feature chronic microglial reactivity that drives neuroinflammation and disease progression. Pharmacological microglial depletion and subsequent repopulation using colony-stimulating factor 1 receptor inhibitors have emerged as a potential therapeutic strategy to reprogram dysfunctional microglia. Despite promising short-term results, the long-term efficacy and pharmacological modulation of repopulated microglia remain poorly understood. Here, we investigated the long-term effects of microglial repopulation alone and in combination with the activation of the cytoprotective nuclear factor erythroid 2 p45-related factor 2 (NRF2) in an in vivo AAV-hTauP301L induced model. Integrating different behavioural, immunohistological and transcriptomic analysis, we evaluated cognitive function, tau pathology, neuronal survival and glial reactivity. We found that, whereas microglial repopulation alone did not significantly affect disease progression, NRF2-driven microglial replenishment sustained cognitive function, prevented hippocampal neuronal loss and restored microglial phenotype. Transcriptomic analyses further revealed that the combined treatment modulated tau- associated mitochondrial gene expression changes. These results highlight the importance of shaping the fate of self-renewed microglia and propose NRF2-mediated microglial repopulation as a potential pharmacological strategy for the treatment of tauopathies., This work was supported by the Spanish Ministry of Science, Innovation and Universities (PDC2022-133809-I00 and PID2021- 125986OB-I00 to MGL; PID2021-122650OB-I00 to MIRF; PID2022- 139936OA-I00 to EN and FPU20/03747 fellowship to LV); and the General Council for Research and Innovation of the Community of Madrid (P2022/BMD-7230 to MGL and 2020-T1/BMD-19886 to ET)., Peer reviewed